期刊文献+

胰腺癌平扫或强化氟脱氧葡萄糖PET—CT图像靶区勾画研究 被引量:1

Gross tumor volume delineation with combination of non-contrast/contrast CT and FDG PET in pancreatic cancer
原文传递
导出
摘要 目的探讨平扫或强化氟脱氧葡萄糖(FDG)PET—CT图像在胰腺癌靶区勾画中的作用。方法回顾分析本院2008--2009年问21例局部晚期不可切除及术后复发胰腺癌患者资料,以相同固定体位分别行平扫CT、PET,其中11例之后行强化CT。将扫描数据输入治疗计划系统,行平扫或强化CT、PET图像融合,分别依据强化CT、平扫CT、平扫PET及平扫或强化PET—CT融合图像勾画大体肿瘤体积(CTV),并用配对或成组t检验比较不同图像GTV大小。结果21例患者平扫GTVCT、平扫GTVPFT、平扫或强化GTVPncT平均值分别为76.9、47.0、44.5cm^2,平扫GTVPE-CT平均体积明显小于平扫GTVCT(z=-3.91,P=0.000)。11例强化GTVCT、强化GTVPET、强化GTVPET-CT平均体积分别为64.1、45.1、49.3cm^2,强化GTVPET-CT平均体积明显小于强化GTVCT(==-2.13,P=0.033),强化GTVPET-CT平均体积与平扫GTVPET-CT相似(z=-0.80,P=0.424)。结论PET和强化或平扫CT的融合图像能提高不可切除胰腺癌靶区勾画准确性,有望降低放疗不良反应。 Objective To investigate the application of non-contrast and contrast-enhanced is FDG PET/CT in the delineation of gross tumor volume (GTV) of pancreatic cancer. Methods Between Jan. 2008 and Dec. 2009, twenty-one patients with unresectable locally advanced pancreatic cancer or recurrent pancreatic cancer after surgery in our hospital had both non-contrast CT and PET images acquired at the same body position. Among the whole group, eleven patients also had contrast CT images. The image data sets were transferred to the treatment planning workstation for registration. Then gross tumor volumes (GTV) were delineated independently using the information of PET images, contrast/non-contrast CT scan and contrast/non-contrast PET-CT fusion images. The differences of mean volume in these different sets of GTV were analyzed. Results For the whole group, the mean volume of non-contrast GTVCT, GTVpET, noncontrast GTVPET-CT were 76. 9 cm3 , 47. 0 cm3 and 44. 5 cm3 , respectively. The mean volume of non-contrast GTVPET-CT was significantly smaller than non-contrast GTVCT ( z = - 3. 91, P = 0. 000). For the eleven patients with contrast CT, the mean volume of contrast GTVcT, GTVpET , contrast GTVpET.CT were 64. 1 cm3 , 45. 1 cm3 and 49. 3 cm3 ,respectively. The mean volume of contrast GTVpET_Cr was significantly smaller than contrast GTVCT (z = - 2. 13, P = 0. 033 ). No significant differences were found between contrast PET-CT and non-contrast PET-CT (z = -0. 80,P = 0. 424). Conclusions Co-registration of PET and contrast/non- contrast CT information in pancreatic cancer may improve the accuracy of GTV delineation, and possibly reduce the adverse effect of irradiation.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2012年第3期255-257,共3页 Chinese Journal of Radiation Oncology
基金 国家自然科学基金青年基金项目(81001001)
关键词 体层摄影术 正电子发射型 体层摄影术 X线计算机 胰腺肿瘤 靶区勾画 Tomography, positron emission Tomography, X-ray computed Pancreatic neoplasms Target volume delineated
  • 相关文献

参考文献11

  • 1Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of ^18F - fluorodeoxy glucose positron emission tomography/eomputed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg, 2009,250 : 957-963.
  • 2Bilimoria KY, Bentrem D J, Ko CY, et al. Validation of the6th edition AJCC pancreatic cancer staging system report from national cancer database. Cancer,2007,110:738-744.
  • 3Mukund S, Didolkar-Cardella W, Coleman-Mark J. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastmintest Surg, 2010,14 : 1547-1559.
  • 4Casneuf V, Delrue L, Kelles A, et al. Is combined ^18F- fluorodeoxy glucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroemerol Belg,2007,70:331-338.
  • 5Van Laere K, Ceyssens S, comparison of IS F-FDG and Van Calenbergh F, et al. Direct 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imag.2005.32:39-51.
  • 6王天禄,李光,党军,陈延治,白露.PET—CT对非小细胞肺癌临床分期及三维适形放疗中靶区勾画的影响[J].中华放射肿瘤学杂志,2011,20(2):99-100. 被引量:5
  • 7任瑞美,付正,于金明,张永明,张国芬,赵献光.FDG PET-CT在食管癌放疗靶区勾画中的作用[J].中华放射肿瘤学杂志,2009,18(6):429-430. 被引量:6
  • 8Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interebserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys,2005,62:70-75.
  • 9Topkan E, Yavuz AA, Aydin M, et al. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Can Res,2008,27:27-41.
  • 10Buchs NC, BUhler L, Bucher P,et al. Value of contrast-enhanced ^18F-fluorodeoxy glucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol, 2011,26: 657-662.

二级参考文献9

  • 1Nishioka T, Shiga T, Shirato H, et al. Image fusion between ^18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys ,2002,53 : 1051-1057.
  • 2Moureau-Zabotto L, Touboul E, Lerouge D, et al. Impact of CT and ^18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys,2005,63:340-345.
  • 3Vrieze O, Haustermans K, De Wever W, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Ra-diother Onco1,2004 ,73 :269-275.
  • 4Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys,2007,67:187-195.
  • 5Konski A,Doss M,Milestone B,et al. The integration of 18-fluorodeoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys,2005 ,61:1123-1128.
  • 6Kim K, Park S J, Kim BT, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg,2001,71:290-294.
  • 7Weber WA, Dietlein M, Hellwig D, et al. PET with ( 18 ) Ffluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin ,2003,42 : 135-144.
  • 8Faria SL, Menard S, Devic S, et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys,2008,70 : 1035-1038.
  • 9Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med ,2003 ,348 :2500-2507.

共引文献9

同被引文献16

  • 1陆以霞,任旭,张玲玲.CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小的关系[J].胰腺病学,2006,6(5):266-268. 被引量:9
  • 2Hidalgo M. Pancreatic cancer[J]. N Eng J Med,2010,362(17) : 1605-1617.
  • 3Dan S, Qiang G, Shu-Xia W, et al. Preliminary discussion on the value of 18F-FDG PET/CT in the diagnosis and early staging of non-mycosis fungoides/S~zary~ s syndrome cutaneous malignant lymphomas[J]. Eur J Radiol,2015,84(7) : 1298 1298.
  • 4Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis,staging, response to treatment, and prognosis of pancreatic eancer[J].AmJ ClinOncoi, 2011,34(2) :111-114.
  • 5Sun Y, Duan Q, Wang S,et al. Diagnosis of pancreatic cancer u- sing 18F FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics[J]. J BUON,2015,20(2):452-459.
  • 6Grieser C, Heine G, Stelter L, et al. Morphological analysis and differentiation of benign cystic neoplasms o~ the pancreas using computed tomography and magnetic resonance imaging[J].Ro- fo,2013,185(3) =219-227.
  • 7Moon SY, Joo KR, So YR,et al. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer [J]. Clin Nucl Med, 2013,38(10);778 78.
  • 8Lee SM, Kim TS, Lee JW, et al. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET[J]. Clin Nucl Med, 2011,36(5) ,331 336.
  • 9Okamoto K, Koyama I,Miyazawa M,et al. Preoperative 18 [F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer re- section[J]. Int J Clin Oncol,2011,16(1) ; 39-44.
  • 10Singh S, Tang SJ, Sreenarasimhaiah J, et al. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a di- agnostic tool for pancreatic cancer and cholangiocarcinoma [J]. Dig Dis Sci,2011,56(8) z 2491-2496.

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部